Key terms
About PRQR
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PRQR news
Mar 14
6:27am ET
Buy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic Disorders
Mar 13
11:15pm ET
Buy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing Platform
Mar 13
1:20pm ET
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX)
Mar 13
7:05am ET
ProQR Therapeutics sees cash runway into mid-2026
Feb 15
7:11am ET
ProQR Therapeutics announces Japanese Axiomer patent upheld
Jan 22
2:08pm ET
Buy Rating Affirmed on ProQR’s Axiomer RNA Editing Platform Amid Promising Preclinical Data
Jan 19
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 19
7:01am ET
ProQR highlights key updates from presentation of Axiomer RNA platform
Jan 05
3:55pm ET
Buy Rating Affirmed for ProQR on Strategic Partnership and Promising Axiomer RNA Editing Platform
Jan 05
7:03am ET
ProQR Therapeutics, RSRT join forces with Axiomer RNA editing collaboration
No recent news articles are available for PRQR
No recent press releases are available for PRQR
PRQR Financials
Key terms
Ad Feedback
PRQR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PRQR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
